In a study led by the Johns Hopkins University School of Medicine and Tufts University School of Medicine, researchers show that a pill form of the drug dronabinol, an FDA-approved synthetic version of marijuana’s main ingredient, THC, reduces agitation in patients with Alzheimer’s by an average of 30%.
Dronabinol shows promise in reducing agitation in Alzheimer’s patients
- Post author:
- Post published:October 2, 2024
- Post category:uncategorized